Paradoxically, both glucagon receptor antagonists (28, 29) and agonists, combined with incretin therapy to boost insulin secretion (30), have shown efficacy for the treatment of obesity and T2D (27, 31, 32). Here, INS is linked to type 2 diabetes mellitus.